Kornimate/medical-research-clean huggingface dataset:
conventional neck exercise with and without scapular corrective exercises in patients with forward head posture

Conditions: Forward Head Posture

Summary: to determine the effects of conventional neck exercises with and without scapular corrective exercises on pain, cervical range of motion and disability in patients with forward head posture


Eligibility criteria:
inclusion criteria: * forward head posture * complain of pain for at least 3months * no history of any therapeutic interventions for the last 3months exclusion criteria: * history of whiplash injury * any cervical surgery * previous history of significant trauma * fracture of cervical or scapula * neurological impairments * cervicogenic head ache

Keywords: forward head posture neck pain conventional neck exercises scapular corrective exercises
patient controlled regional analgesia following carpal tunnel release: a double-blind study using distal perineural catheters

Conditions: Carpal Tunnel Syndrome

Summary: this study was done with the primary aim of assessing the efficacy (as calculated by pain intensity difference) of patient controlled regional analgesia (pcra) technique against oral analgesics, which has been the standard of care at our hospital. secondary objectives were to analyze the volume and dose of la that should be given, patient satisfaction and the long-term outcome for patients treated with the pcra technique.


Eligibility criteria:
inclusion criteria: * patients with clinically established carpel tunnel syndrome * surgery performed under local anesthesia exclusion criteria: * chronic pain requiring analgesics

Keywords: anesthetics local ropivacaine surgery hand carpel tunnel carpal tunnel surgery
specified drug-use surveillance of fabhalta capsules

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Summary: this is a multicenter, single-arm, non-interventional study (nis) with a central registration system and an all-case surveillance system. the observation period is 48 weeks after the start of treatment with fabhalta.

the observation period will be 48 weeks after the start of treatment with fabhalta. for patients in whom treatment with fabhalta is discontinued within 48 weeks after the start of the treatment, adverse events occurring by the last day of the treatment + 30 days and concomitant drugs will be monitored and recorded in crfs.

Eligibility criteria:
inclusion criteria: all patients who received fabhalta. · exclusion criteria: patients receiving fabhalta for an unapproved indication under the clinical trials act or gcp.

Keywords: paroxysmal nocturnal hemoglobinuria pnh fabhalta
chemosensitivity testing to assign treatment for patients with stage iii or stage iv ovarian cancer

Conditions: Ovarian Cancer

Summary: rationale: chemosensitizers may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug. purpose: randomized phase iii trial to study the effectiveness of chemosensitivity testing to assign treatment for patients with stage iii or stage iv ovarian cancer who have undergone surgery.

objectives: i. determine whether the use of a chemosensitivity assay to assign treatment improves the time to progression and response rates of patients with stage iii/iv ovarian cancer. outline: this is a randomized study. patients are stratified according to size of tumor after debulking surgery, stage, and swiss group for clinical cancer research center where treatment is received. within 14 days after patients undergo debulking surgery, they are randomized to one of two treatment arms. arm i: patients randomized to this arm receive one of six treatment regimens: regimen a - cisplatin/cyclophosphamide regimen b - cisplatin/cyclophosphamide/doxorubicin regimen c - carboplatin regimen d - carboplatin/cyclophosphamide regimen e - cisplatin/paclitaxel regimen f - carboplatin/paclitaxel arm ii: patients who are randomized to this arm are assigned a treatment regimen based on a chemosensitivity assay of tumor specimens collected after debulking surgery. if no valid assay result is obtained, patients receive carboplatin/cyclophosphamide. treatment is repeated every 3-4 weeks for a total of 6 courses. up to 4 more courses may be administered if a partial response is demonstrated. patients are followed every 3 months for the first 2 years and every 6 months thereafter. projected accrual: approximately 300 patients will be accrued for this study over 6 years.

Eligibility criteria:
disease characteristics: histologically/pathologically confirmed stage iii and iv ovarian cancer complete surgical staging and debulking including total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and biopsies of suspicious lesions (if feasible) required no low malignant potential histology without any invasive lesions in the peritoneum patient characteristics: age: 80 and under performance status: 0-3 life expectancy: not specified hematopoietic: not specified hepatic: not specified renal: not specified other: no disorder that would prevent the application of any protocol treatment prior concurrent therapy: see disease characteristics

Keywords: stage iii ovarian epithelial cancer stage iv ovarian epithelial cancer
chipp2: a trauma-informed program for city school parents

Conditions: Parenting

Summary: purpose of this study is to assess the prevalence of adverse childhood experiences (aces) and positive childhood experiences (pces) among parents enrolled in the chicago parent program (chipp) in their child's school and whether those experiences are associated with a) parents' participation in chipp and b) program benefits for parents and children.

purpose of this study is to assess the prevalence of adverse childhood experiences (aces) and positive childhood experiences (pces) among parents enrolled in the chicago parent program (chipp) in their child's school and whether those experiences are associated with a) parents' participation in chipp and b) program benefits for parents and children. parents who enroll in chipp groups in their child school are eligible to participate in this study. data on aces, and pces are collected at baseline. parent perceptions of their children's behavior problems and their engagement in early learning are collected at baseline and post-intervention data. parent satisfaction with chipp and their sense of connection with other parents in their chipp group are measured at post-intervention only.

Eligibility criteria:
inclusion criteria: * parent of child enrolled in chicago parent program group in baltimore city public schools * parent age 18-99 * child must be between 3-8 years old exclusion criteria: * parent does not speak english or spanish

Keywords: early childhood adverse childhood events
thrombin generation and prediction of thromboembolic events in oncology patients at risk

Conditions: Solid Carcinoma

Summary: coagulation is a complex system which, through the action of thrombin, leads to the formation of fibrin, which stabilises the platelet clot. any disturbance in the balance between procoagulant and anticoagulant factors can tip the physiological process either towards a state of hypercoagulability leading to thrombosis or hypocoagulability responsible for bleeding. due to a number of factors, cancer is associated with a state of hypercoagulability, leading to thrombosis. the incidence of venous thromboembolism (vte) in cancer patients varies from 15 to 20% depending on the type of cancer, the stage of the disease and the associated treatments (oncorif data, november 2021). the risk of venous thromboembolism (vte) is greatly increased in cancer patients (rr x 3 to 6) and doubled in the case of associated chemotherapy (1). vte is a poor prognostic factor, occurs mainly in the first 6 months after diagnosis and is the second leading cause of death in cancer patients. at present, haemostasis tests performed in medical laboratories independently explore the different coagulation pathways but do not allow the overall haemostatic profile of a hyper- or hypocoagulable patient to be assess. based on this knowledge base, the aim of our study will be to monitor thrombogram profiles during the management of patients with tumours at high risk of thromboembolism (lung, pancreas, stomach, glioblastoma) and to correlate these profiles with the risk of a thromboembolic event occurring in these patients. the aim of the project is to validate a simple predictive test (suitable for clinical use) for the risk of thromboembolism in these patients. these analyses will also make it possible to monitor the impact of chemotherapy on changes in the thrombin generation test in patients.

biological blood samples will be taken specifically for research purposes. as far as possible and depending on the patient's schedule, a sample will be taken every month (during a consultation and/or a course of chemotherapy) and for the 12 months following the initiation of systemic treatment

Eligibility criteria:
inclusion criteria: 1. patient aged \> 18 years, 2. patient with a solid cancer at high risk of thrombosis, whether metastatic or not (lung, pancreatic, gastric or glioblastoma cancers)1, 3. patients who have not received any systemic treatment for their cancer, 4. an informed patient who does not object to the use of data for research purposes and who has consented to the collection, use and storage of biological samples. exclusion criteria: 1. patient who has had a vte in the 12 months preceding the diagnosis of cancer, 2. patient on low molecular weight heparins, standard unfractionated heparins and anti-vitamin k2, 3. women who are pregnant, likely to become pregnant or who are breast-feeding, 4. persons deprived of their liberty, under court protection, under curators or under the authority of a guardian, 5. unable to undergo medical monitoring of the trial for geographical, social or psychological reasons.
prostacyclin's effect on platelet responsiveness

Conditions: Acute Kidney Failure

Summary: the researchers investigated the influence of a prostacyclin analogue (pgia) versus unfractionated heparin (ufh) on ex vivo platelet function, during continuous venovenous hemodiafiltration.

context and purpose of the study: prospective, randomized comparison of a pgia versus ufh as circuit anticoagulant. platelet responsiveness was assessed from peripheral blood by light-transmittance aggregometry (lta) induced by collagen and adp, at baseline, 4 and 24 hrs after treatment onset. platelet function was also assessed in blood samples collected in the circuit before and after the filter. the setting was a university hospital intensive care unit. 23 icu patients with acute renal failure needing cvvhdf were studied during standard cvvhdf therapy, at random infusion in the extracorporeal circuit of pgia or ufh.

Eligibility criteria:
inclusion criteria: * critically patients ill patients with acute kidney failure (aki) needing renal replacement therapy exclusion criteria: * therapy with aspirin or other non-steroidal anti-inflammatory drugs in the previous 7 days * concomitant treatment with other extracorporeal organ-assist devices any other drug affecting coagulation or platelets

Keywords: anticoagulation prostacyclin heparin renal replacement therapy kidney failure acute platelet aggregation
the effect of prolonged inflation time during stents deployment for st-elevation myocardial infarction

Conditions: Acute ST-elevation Myocardial Infarction

Summary: the purpose of this study is to determine whether prolonged inflation time on drug-eluting stents deployment for st-elevation myocardial infarction was better than conventional stents deployment.


Eligibility criteria:
inclusion criteria: * men and women ≥18 years with st-elevation myocardial infarction; * patients with stemi and ischemic symptoms of less than 12 hours'duration; * patients with stemi and ischemic symptoms of less than 12 hours' duration who have contraindications to fibrinolytic therapy, irrespective of the time delay from fmc; * patients with stemi if there is clinical and/or ecg evidence of ongoing ischemia between 12 and 24 hours after symptom onset; * when angiography was completed, guide wire could cross the lesion in the culprit vessel, timi≥1，with feasibility to direct stenting exclusion criteria: * cardiac shock, or acute severe heart failure; * the lesion was highly calcified, excessive proximal tortuosity,left main artery lesion, restenosis lesion,vein graft lesion,total occlusions; * true bifurcation lesions; * stenosis≤50% and timi flow grade 3; * history of pci in target vessel; * diameter of the target vessel less than 2 mm; * severe liver and kidney dysfunction; * inability to give informed written consent.
exploratory study of cellular reservoirs in blood from hiv infected patients

Conditions: HIV Infection

Summary: this study evaluates the impact of highly active antiretroviral therapy on the size of the latent viral reservoirs in resting cd4+ t cells and monocytes in hiv positive patients. the activation state of the cells will be assessed, by measuring the activation of akt, to determine its influence on the size of the viral reservoirs.


Eligibility criteria:
inclusion criteria: * hiv infected patients under highly active anti-retroviral therapy (haart) or naïve from treatment exclusion criteria: * age limits * pregnancy * legal restrictions to consent
a study to assess the pharmacokinetics of certolizumab pegol in adults with active rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the purpose of the study is to evaluate the pharmacokinetics and safety of certolizumab pegol in adults with active rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * participant must be 18 to 69 years of age inclusive, at the time of signing the informed consent * participant must have a diagnosis of moderately-to-severely active rheumatoid arthritis (ra) * participant must have had an inadequate response to, or intolerance to, at least 1 disease modifying antirheumatic drug (dmard) (nonbiologic or biologic) * participant has a negative interferon-gamma release assay (igra) at screening * participant has a body mass index within the range 18.0 kg/m2 to 35.0 kg/m2 (inclusive) * male or female * a female participant is eligible to participate if: i) she is not pregnant, ii) not breastfeeding, iii) at least one of the following conditions applies: 1. not a woman of childbearing potential (wocbp) or 2. a wocbp who agrees to follow the contraceptive guidance during the treatment period and until the safety follow-up (sfu) visit exclusion criteria: * participant has a known hypersensitivity to any components of the study medication(including polyethylene glycol) or comparative drugs (and/or an investigational device) as stated in this protocol * participant has clinically significant electrocardiogram (ecg) abnormalities at screening * participant has previously been exposed to certolizumab pegol (czp) * participant has failed treatment with ≥1 tumor necrosis factor (tnf) α inhibitor or was a primary failure for any tnfα antagonist. a primary failure is defined as no clinical disease improvement within the first 12 weeks of treatment (study participants who demonstrated clinical response within 12 weeks of treatment and subsequently lost response after 12 weeks of treatment are eligible) * participant has received a live vaccination within 6 weeks prior to screening or intends to have a live vaccination during the course of the study or within 3 months following czp treatment in the study * participant has received any investigational drug or experimental procedure within 90 days prior to the first dose of impinvestigational medicinal product (imp) * participant has a laboratory abnormality at screening, including any of the following: 1. \>3.0x upper limit of normal (uln) of any of the following: alanine aminotransferase (alt), aspartate aminotransferase (ast), alkaline phosphatase (alp); or \>uln total bilirubin (\>1.5x uln total bilirubin if the participant has a documented pre-study diagnosis of gilbert's syndrome) 2. white blood cell count \<3.00x103/μl 3. absolute neutrophil count (anc) \<1.5x103/μl 4. lymphocyte count \<500 cells/μl 5. hemoglobin \<8.5 g/dl 6. any other laboratory abnormality, which, in the opinion of the investigator, will prevent the study participant from completing the study or will interfere with the interpretation of the study results

Keywords: rheumatoid arthritis phase 1 cimzia certolizumab pegol electrochemiluminescent immune-assay
celecoxib for the treatment of non-muscle invasive bladder cancer

Conditions: Non Muscle Invasive Bladder Cancer

Summary: the treatment of non-muscle invasive bladder cancer (nmibc) is problematic given the variable natural history of the disease. although contemporary treatment options are limited, new targets and new approaches are under investigation for preventing bladder cancer recurrence and progression. among those, cox-2 is a promising target since plays an important role in urothelial carcinogenesis and icox-2 selective inhibitors, like celecoxib, effectively inhibit tumor development and growth and enhances survival, in bladder cancer in vitro and in vivo models. therefore, the investigators conducted a pilot study of celecoxib to prevent recurrence in patients with intermediate risk nmibc.


Eligibility criteria:
inclusion criteria: * histologically proven urothelial bladder cancer * intermediate risk nmibc * ecog performance status ≤ 2 or karnofsky score ≥ 60% * imaging study excluding upper urinary tract tcc exclusion criteria: * pregnant and lactating women; * advanced co-existing medical or psychiatric disorders; * positive history of gastro-intestinal disease (peptic ulcer, inflammatory disease), intestinal bleeding; * history of allergy to sulfonamide drugs; * concomitant investigational medications.

Keywords: intermediate risk cox-2 inhibitors
identification of innovative biomarkers to predict outcomes in hepatocellular carcinoma treated with tremelimumab and durvalumab

Conditions: Hepatocellular Carcinoma

Summary: several cancer immunotherapies that target the pd-l1/pd-1 pathway (i.e., checkpoint inhibitors) show promising clinical activity in patients with hcc. in particular, atezolizumab selectively targets pd-l1 to prevent interaction with receptors pd-1 and b7-1, thus reversing t-cell suppression. moreover, atezolizumab in combination with bevacizumab, a monoclonal antibody that targets vegf and inhibits angiogenesis, is associated with an objective response rate of 27.3% (cheng et al. 2021; finn et al. 2020). this tumor response has led to fda (food and drug administration) and ema (european medicines agency) approvals, in first-line treatment in unresectable hcc. combinations studies evaluating anti-ctla4 and anti-pd1/pdl1 antibodies displayed greater benefits (abou-alfa et al. 2022). in the phase 3 himalaya study (nct03298451) in uhcc, a single priming dose of tremelimumab (anti-ctla-4) plus durvalumab (anti-pd-l1) in the stride (single tremelimumab regular interval durvalumab) regimen significantly improved os versus sorafenib; durvalumab monotherapy was noninferior to sorafenib for os. in the himalaya study, stride regimen induced long term survival (defined as the absence of progression above 36 months following inclusion) in 103 out of the 393 patients exposed to this strategy (26%). the identification of biomarkers allowing the prediction of immunotherapy efficacy in hcc is still an unmet medical need.


Eligibility criteria:
inclusion criteria: 1. signed informed consent 2. histologically confirmed hepatocellular carcinoma 3. locally advanced, metastatic, or unresectable disease 4. patient who had not previously received systemic anti-cancer treatment and are eligible to stride therapy according to investigator decision in routine care and who have no contraindications to stride treatment according to approved product label. 5. measurable disease defined according to recist v1.1 guidelines (note: previously irradiated lesions can be considered as measurable disease only if disease progression has been unequivocally documented at that site since radiation.) 6. age ≥ 18 years 7. patient affiliated to or beneficiary of french social security system 8. ability to comply with the study protocol, in the investigator's judgment. exclusion criteria: 1. patients previously exposed to anti-tumor immunotherapy as anti-pd-1, anti-pd-l1, or anti-ctla4 agent or any immune therapy. 2. patient with any medical or psychiatric condition or disease, which would make the patient inappropriate for entry into this study 3. patient under guardianship, curatorship or under the protection of justice

Keywords: biomarker, immunotherapy
assessment of the effectiveness of new clinical guidelines for differential diagnosis and management of common hiv/aids-related conditions in mozambique

Conditions: Anemia; Fever; HIV Positive

Summary: utilizing funding through the president´s emergency plan for aids relief (pepfar) this project seeks to assess the effectiveness of a subset of the new mozambican clinical guidelines for the diagnosis, initial management, and follow-up ( \>1 follow-up visit to determine response to initial and/or second-line therapy) of common signs and symptoms in hiv-infected adult patients as used under field conditions by mozambique-based clinicians in moh health facilities in zambézia province, mozambique. the operational feasibility of the new guidelines will be described; they will be compared to the previous standard of care for the problem(s) of interest, and the clinical importance of differences between guidelines designed for mozambican non-physician clinicians and new guidelines (also issued in late 2009) for mozambican physicians will be described. the subset of guidelines to be addressed in the current phase of this 2-year project includes algorithms for diagnosis and management of acute fever, persistent fever, and anemia.


Eligibility criteria:
inclusion criteria: * \> 18 years old * hiv-infected * fever \> 37.5° c or history of fever * anemia with recorded hemoglobin level \<10 mg/dl exclusion criteria: * primary language/dialect is not spoken or understood by any member of the study team. * participants who meet algorithm-driven definitions of "danger signs" related to the condition of interest at the time of screening * pregnant women will be excluded only if they meet the following criteria (in labor, or in need of emergency caesarean section or dilatation and curettage)

Keywords: adult hiv positive patients